Annick Desjardins, MD, FRCPC
Duke University
9
9
3
N/A
0
10
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+12 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (9)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Kevin A camphausen, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Thomas Kaley, MD
Memorial Sloan Kettering Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Katherine E Warren, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Daniel Landi, MD
Duke University
Shared therapeutic areas:
Worked with same sponsors:
David A. Reardon, MD
Duke Health
Shared therapeutic areas:
Worked with same sponsors:
Sean Grimm, MD
Northwestern University
Shared therapeutic areas:
Steven Chmura, MD
University of Chicago
Shared therapeutic areas:
Jeffrey Raizer, MD
Northwestern University
Shared therapeutic areas:
Adam Mamelak, MD
Cedars-Sinai Medical Center
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (9)
Showing 9 of 9 trials
DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab
Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma
Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma
A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM)
Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG)
Panitumumab and Irinotecan for Malignant Gliomas
Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)
Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure
Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma
All 9 trials loaded